GlassScriptPhysician profile
Martin Bautista
NPI 1144249327
$5,482.00
in general payments reported to CMS, 2019-2025
22 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $1,160 · 2021: $1,233 · 2022: $888 · 2023: $602 · 2024: $380 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,267 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.62 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,808.42 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Merck Sharp & Dohme LLC | $544.43 | 2019-2023 | Steglatro, Belsomra |
| Pfizer INC. | $300.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.14 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.92 | 2019-2023 | Glassia |
| Lilly USA, LLC | $215.46 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $207.34 | 2021-2023 | Ozempic |
| Xeris Pharmaceuticals, INC. | $121.32 | 2023-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $119.44 | 2022 | |
| Mylan Specialty L.P. | $103.57 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $93.79 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.23 | 2020-2021 | |
| Amgen INC. | $74.54 | 2019-2021 | |
| Exact Sciences Corporation | $73.65 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $56.44 | 2021-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $47.32 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $36.68 | 2025 | |
| Idorsia Pharmaceuticals US INC | $35.21 | 2023 | Quviviq |
| Kerecis Limited | $19.30 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Gilead Sciences, INC. | $14.51 | 2020 | |
| Allergan, INC. | $14.51 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Bautista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.